Treatment Free Remission after Nilotinib Plus Peg-Interferon Alpha Induction and Peg-Interferon Alpha Maintenance Therapy for Newly Diagnosed Chronic Myeloid Leukemia Patients; The Tiger Trial

Hochhaus, Andreas; Burchert, Andreas; Saussele, Susanne; Baerlocher, Gabriela M; Mayer, Jiří; Brümmendorf, Tim H.; La Rosée, Paul; Heim, Dominik; Krause, Stefan W.; le Coutre, Philipp; Rinke, Jenny; Lange, Thoralf; Fabarius, Alice; Lorch, Marcel; Hanel, Mathias; Stegelmann, Frank; Franke, Georg-Nikolaus; Radsak, Markus P.; Kunzmann, Volker; Zackova, Daniela; Himsel, Danny; Kohn, Denise; Lang, Thomas; Hehlmann, Rüdiger; Fabisch, Christian; Ernst, Thomas; Pfirrmann, Markus

doi:10.1182/blood-2023-182792

Treatment Free Remission after Nilotinib Plus Peg-Interferon Alpha Induction and Peg-Interferon Alpha Maintenance Therapy for Newly Diagnosed Chronic Myeloid Leukemia Patients; The Tiger Trial

Background: The TIGER-trial (NCT01657604) is a multicenter, randomized phase III study to evaluate efficacy and tolerability of nilotinib (NIL) vs NIL+pegylated interferon alpha2b (IFN) combination therapy with IFN maintenance as first-line treatment for patients (pts) with chronic myeloid leukem…